IBS Treatment Companies
In the realm of gastrointestinal health, IBS Treatment companies specialize in developing therapies and interventions for irritable bowel syndrome (IBS). These organizations contribute to
In the realm of gastrointestinal health, IBS Treatment companies specialize in developing therapies and interventions for irritable bowel syndrome (IBS). These organizations contribute to
Latest Irritable Bowel Syndrome (IBS) Treatment Companies Updates:
Ironwood Pharmaceuticals: Promising Phase 3 data for Linzess (linaclotide) in adult IBS-C patients with constipation-predominant symptoms, potentially expanding treatment options.
Takeda Pharmaceuticals: Positive Phase 2a results for TAK-786, a novel oral guanylate cyclase-C (GC-C) stimulator, showing potential for treating both IBS-C and IBS-D.
Allergan: Launched a Phase 2 study for AG041270, a new investigational therapy targeting neurokinin-1 (NK-1) receptors, for treating IBS-D.
AstraZeneca: Received FDA approval for Trinessa (drospirenone, ethinyl estradiol, and levofloxacin) for treating moderate-to-severe IBS-C in women with endometriosis.
Suven Therapeutics: Launched SB207798, a first-in-class, peripherally acting G-protein coupled receptor 54 (GPR54) agonist, for treating CIC in adults, which could potentially be repurposed for IBS in the future.
Synergy Pharmaceuticals: Expanded market access for Trulance (plecanatide) in Canada for treating adults with IBS-C.
List of Irritable Bowel Syndrome (IBS) Treatment Key companies in the market:
IBS Treatment Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)